Pruritus – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Pruritus Market Outlook

Thelansis’s “Pruritus Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pruritus treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pruritus Overview

Pruritus, or itching, is a prevalent complaint that dermatologists and primary care physicians frequently encounter. It is one of the most common dermatological issues, and although generally considered harmless, it can negatively impact a patient’s well-being and become debilitating when severe. The dermatologic causes of pruritus include conditions such as xerosis (dry skin), atopic dermatitis, scabies, dermatitis herpetiformis, lichen simplex chronicus, psoriasis, lichen planus, contact dermatitis, fungal infections, insect bites, pediculosis (lice infestation), urticaria (hives), sunburn, polymorphous light eruption, pityriasis rosea, as well as triggers like electrostatic charges from nylon and wool friction, plaster of Paris casts, fiberglass, and other irritants. The itch can be classified into four categories: cutaneous itch, neuropathic itch, neurogenic itch, and psychogenic itch. Cutaneous itch, also known as pruritoceptive itch, is caused by skin inflammation. Neuropathic itch occurs due to damage to the nervous system along the afferent nerve pathway and is often observed in conditions like herpetic neuralgia, multiple sclerosis, and brain tumors. Neurogenic itch originates centrally without evidence of neuronal pathology, commonly seen in cholestasis. Lastly, psychogenic itch is associated with delusional states, such as parasitophobia. Histamine is the most prominent substance involved in mediating itch. It is stored in mast cells and keratinocytes. Antihistamines can help treat urticaria and other allergic causes of pruritus. However, apart from providing sedation to aid sleep, antihistamines do not consistently alleviate itch from all causes.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Pruritus – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034